Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.

9 , 10 A high proportion (~68.0%) of patients who received low‐dose perampanel (4 mg/day) in the Core Study of Study 335 were also receiving EIASMs, which could be a possible reason why the reductions in FOS frequency at this dose did not reach statistical significance compared with placebo. 5 To this end, we have conducted a further post hoc analysis to explore the effect of EIASMs on the efficacy and safety of low‐dose perampanel.

also in 111,027 other papers